Evidence map›Paper›PMID 39652739›Full record

ReviewBlood cancer discovery2025

The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.

Christopher M Sturgeon, Elvin Wagenblast, Franco Izzo, Eirini P Papapetrou

Abstract readReview
In one paragraph

Review in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher M SturgeonCenter for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0003-1508-4414
Elvin WagenblastCenter for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-0709-2759
Franco IzzoCenter for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-5813-6504
Eirini P PapapetrouCenter for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0001-7002-417X

Funding

NIH FIRST Cohort Cluster Hiring Initiative at Icahn School of Medicine at Mount SinaiU54CA267776 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nihal Mohamed · 2021 to 2026
$17.4M
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutationsR01CA271331 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.3M
Impact of mutational order on molecular mechanisms of oncogenesisR01CA260711 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.2M
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasmsR01CA271418 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2023 to 2026
$2.7M
Overcoming Therapy Resistance in Fusion Oncoprotein Driven Pediatric LeukemiaR01CA292503 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elvin Wagenblast · 2024 to 2026
$2.4M
Embryonic natural killer cell development and functionR01HL151777 · NHLBI · WASHINGTON UNIVERSITY · PI PALIS, JAMES, STURGEON, CHRISTOPHER MICHAEL · 2020 to 2023
$2.3M
Mesodermal Commitment of the Definitive Hematopoietic ProgramR01HL145290 · NHLBI · WASHINGTON UNIVERSITY · PI STURGEON, CHRISTOPHER MICHAEL · 2019 to 2023
$2.1M
Engineering pluripotent stem cells to evade and promote immunityR01EB035491 · NIBIB · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deepta Bhattacharya, Christopher Michael Sturgeon · 2024 to 2026
$1.8M
Intrinsic and Extrinsic Factors Contributing to Trisomy 21 PreleukemiaR01CA290681 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elvin Wagenblast · 2024 to 2026
$1.3M
Characterization of multilineage definitive hematopoietic progenitors from human pluripotent stem cellsR01HL172940 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI STURGEON, CHRISTOPHER MICHAEL · 2024 to 2025
$1.2M
American Society of Hematology (ASH) 204377-01Edward P Evans FoundationLeukemia and Lymphoma Society (LLS)National Cancer Institute (NCI) R01CA271418National Cancer Institute (NCI) U54CA267776NCI NIH HHS R01 CA260711NCI NIH HHS R01 CA271331NCI NIH HHS R01 CA271418NCI NIH HHS R01 CA290681NCI NIH HHS R01 CA292503NCI NIH HHS U54 CA267776NHLBI NIH HHS R01 HL145290NHLBI NIH HHS R01 HL151777NHLBI NIH HHS R01 HL172940NIBIB NIH HHS R01 EB035491
6 · The paper itself

Abstract

significanceIn recent years, remarkable technological advances have illuminated aspects of the pathogenesis of myeloid malignancies-yet outcomes for patients with these devastating diseases have not significantly improved. We posit that a synthesized view of the three dimensions through which hematopoietic cells transit during their healthy and diseased life-clonal evolution, stem cell hierarchy, and ontogeny-promises high yields in new insights into disease pathogenesis and new therapeutic avenues.

Indexed as

Cell DifferentiationClonal EvolutionLeukemiaAnimalsHematopoietic Stem CellsHumansNeoplastic Stem Cells

Identifiers

PMID39652739
PMCPMC11876951

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.